Conference item icon

Conference item

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease

Abstract:
Vedolizumab is a gut-selective antibody to α4β7 integrin approved for the treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) in adult patients. Only 3% of patients in pivotal trials of vedolizumab were aged 65–80 years and patients aged >80 years were excluded. We analysed post marketing safety data to investigate whether older patients reported a different safety profile with vedolizumab compared with younger patients.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx180.588

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDM Experimental Medicine
Oxford college:
Linacre College
Publisher:
Oxford University Press Publisher's website
Volume:
12
Issue:
supplement_1
Pages:
S337-S338
Publication date:
2018-01-16
Acceptance date:
2017-12-22
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Pubs id:
pubs:844395
URN:
uri:b8f7c7b8-a0fd-4fca-a419-0845ea0a8b23
UUID:
uuid:b8f7c7b8-a0fd-4fca-a419-0845ea0a8b23
Local pid:
pubs:844395

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP